RxDoctor Payments DataLook up a doctor →

Maithili Chitnavis, MD

Internal Medicine · Charlotte, NCNPI 1720378730

Payments from drug & device makers

$536,256in general payments, 2019–2025

Across 463 payments — averaging $1158.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$204K
  • AbbVie$137K
  • Lilly USA, LLC$116K
  • Takeda Pharmaceuticals U.S.A., Inc.$37K
  • Bristol Myers Squibb$29K
  • Johnson & Johnson$10K
  • plus $3K from 12 others
$6,626in research payments, 2019–2025

Across 5 payments — averaging $1325.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$12,1215%
  • Speaking & faculty fees$215,28481%
  • Travel & lodging$29,16911%
  • Food & beverage$9,8904%
  • Education$2010%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$536,256 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,858
Medicare patients
81
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$674,430
Skyrizi On-BodyRisankizumab-Rzaa13$271,846
RinvoqUpadacitinib15$131,926
SimponiGolimumab13$90,982
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates46$3,133
Mesalamine15$2,931
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl37$585
Omeprazole20$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$9,914$765,41337 claims
AbbVieRinvoq$137,392$131,92615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →